CG Oncology

US · CGON #1929 by market cap Listed 2024

62.38 -1.26 -1.98%

Live - 5344 symbols - heartbeat 463s ago · 2026-10-08 04:49

Pre-market 61.56 -1.31%

After-hours 62.38 0.00%

Market cap: 5.53B
P/E (TTM): -23.19
P/B: 5.37
EPS: -2.08
Div yield: 0.00%
52W pos: 59%

Reader sentiment Are you bullish or bearish on CGON?

Anonymous reader poll. Unscientific, not investment advice.

About CG Oncology

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Dallas, TX.

Founded: 2010
CEO: Mr. Arthur Kuan
Employees: 142
Headquarters: Dallas, Texas, United States of America
Fiscal year end: 12-31
Website: cgoncology.com

Company profile

Exchange: US
Symbol: CGON
Market-cap rank: #1929
Listing date: 2024-01-25
Market cap: 5.53B
Float cap: 4.26B
Shares out: 88.64M
Float shares: 68.28M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 04:49:36 · For reference only, not investment advice and not tailored to your situation.